BR100 Increased By (0.99%)
BR30 Increased By (0.38%)
KSE100 Increased By (1.06%)
KSE30 Increased By (1.14%)
BECO 5.39 Increased By ▲ 0.07 (1.32%)
BML 56.48 Increased By ▲ 1.39 (2.52%)
BOP 35.09 Increased By ▲ 0.05 (0.14%)
CNERGY 8.17 Increased By ▲ 0.08 (0.99%)
DCL 11.44 Increased By ▲ 0.08 (0.7%)
FCCL 57.55 Increased By ▲ 1.36 (2.42%)
FCSC 5.00 Decreased By ▼ -0.01 (-0.2%)
FFL 17.88 Increased By ▲ 0.20 (1.13%)
FNEL 1.25 Increased By ▲ 0.01 (0.81%)
HUMNL 11.17 Increased By ▲ 0.24 (2.2%)
KEL 8.54 Decreased By ▼ -0.03 (-0.35%)
KOSM 6.73 Increased By ▲ 0.24 (3.7%)
MLCF 106.91 Increased By ▲ 0.40 (0.38%)
NBP 198.50 Decreased By ▼ -1.26 (-0.63%)
PACE 11.07 Increased By ▲ 0.05 (0.45%)
PAEL 45.45 Increased By ▲ 0.45 (1%)
PIAHCLA 31.43 Increased By ▲ 2.86 (10.01%)
PIBTL 19.08 Increased By ▲ 0.81 (4.43%)
PPL 242.62 Decreased By ▼ -1.87 (-0.76%)
PRL 35.67 Increased By ▲ 0.73 (2.09%)
PTC 65.52 Decreased By ▼ -0.30 (-0.46%)
SEARL 94.54 Increased By ▲ 0.49 (0.52%)
SSGC 32.08 Increased By ▲ 1.25 (4.05%)
TELE 8.87 Increased By ▲ 0.17 (1.95%)
THCCL 65.66 Increased By ▲ 0.67 (1.03%)
TPLP 10.73 Increased By ▲ 0.47 (4.58%)
TREET 25.11 Increased By ▲ 0.24 (0.97%)
TRG 63.67 Increased By ▲ 0.31 (0.49%)
WAVES 10.70 Increased By ▲ 0.05 (0.47%)
WTL 1.25 Increased By ▲ 0.01 (0.81%)
By

BRUSSELS: A vaccine scheme co-led by the World Health Organization is setting up a compensation fund for people in poor nations who might suffer any side-effects from COVID-19 vaccines, aiming to allay fears that could hamper a global rollout of shots.

The mechanism is meant to avoid a repetition of delays experienced a decade ago during the H1N1 swine flu pandemic, when inoculations were slowed down in dozens of low-income countries because there was no clear liability.

The scheme is being set up by the promoters of the COVAX vaccine facility, which is co-led by the WHO and GAVI, a global vaccine alliance, a COVAX document published on Thursday said. COVAX aims to distribute at least 2 billion effective shots around the world by the end of next year.

The scheme could foot the bill for 92 low-income countries, mostly in Africa and South-East Asia, meaning their governments would face little or no costs from claims brought by patients, should anything go unexpectedly wrong after a COVAX-distributed vaccine is administered.

However dozens of middle-income countries, such as South Africa, Lebanon, Gabon, Iran and most Latin American states, would not be offered this protection. "The COVAX Facility is developing a system to provide compensation to those individuals in any of the 92 economies ... that suffer unexpected SAEs (serious adverse events) associated with such vaccines or their administration," COVAX said.

Comments

Comments are closed for this article.